Docetaxel added to androgen deprivation therapy (ADT) was the most cost-effective first-line regimen for patients with ...

One type of androgen deprivation therapy may speed coronary plaque growth in men being treated for localized prostate cancer.

Significantly less progression, especially unstable lesions, with relugolix versus leuprol ...

The REVELUTION (Relugolix versus Leuprolide Cardiac) trial compared coronary plaque after 2 types of androgen deprivation therapy (ADT) for prostate cancer.

PEACE-2 finds adding cabazitaxel to ADT plus radiotherapy fails to improve survival in high-risk localized prostate cancer, while increasing severe toxicities and deaths.

Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of international research on androgen deprivation therapy (ADT) for prostate cancer ...

PSMA-617 to androgen deprivation therapy (ADT) with androgen receptor pathway inhibitor (ARPI) bettered disease control in patients with metastatic hormone-sensitive prostate cancer (mHSPC), according ...

Immunotherapy has been generally ineffective for prostate cancer because the tumors are considered immunologically "cold," meaning they do not attract enough immune cells to mount a strong attack.

"There is no evidence that ADT followed by brachytherapy increases the chance of cure in comparison to other treatments, such an external beam radiation therapy alone, in these men with favorable risk ...

New data presented at the American Urological Association (AUA) annual meeting further supported the use of darolutamide (Nubeqa) in combination with androgen deprivation therapy (ADT) for patients ...